Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42066 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL232834 | 1.00 | HRH1 (0.62) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL27928248 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL4374172 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Hydrochloric Acid SCHEMBL16032107 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| Bromide SCHEMBL28648396 | 0.98 | HRH1 (0.60) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7417534 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL4281797 | 0.88 | HRH1 (0.68) | HRH1RIPK1LMNAAOC3HTR2A | |
| Cadaverine Tartrate SCHEMBL9851431 | 0.88 | HRH1 (0.50) | HRH1RIPK1LMNAAOC3HTR2A | |
| SCHEMBL7373079 | 0.86 | HRH1 (0.59) | HRH1RIPK1LMNAAOC3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765766-B1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-09-25 | — | — | EP | claimed |
| US-7294744-B2 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-11-13 | — | — | US | claimed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1765766-A1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006005476-A1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-01-19 | — | — | WO | claimed |
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-01-12 | — | — | US | claimed |
| US-20030096019-A1 | Methods of using norfluoxetine | SEPRACOR INC. | 2003-05-22 | — | — | US | claimed |
| US-6235737-B1 | APPLYING COMPOUND TO ADJUST CERAMIDE CONCENTRATION | GILLETTE COMPANY, THE | 2001-05-22 | — | — | US | claimed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | claimed |
| JP-2193951-A | — | — | None | — | — | JP | disclosed |
| CN-116217415-B | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2024-06-18 | — | — | CN | disclosed |
| EP-4188932-A1 | COMPOUNDS | The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, (IE) | 2023-06-07 | — | — | EP | disclosed |
| CN-116217415-A | Method for synthesizing chiral 3-amino-1-phenylpropanol and chiral 3- (methylamino) -1-phenylpropanol | 武汉大学 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022023438-A1 | COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-02-03 | — | — | WO | disclosed |
| EP-0818431-A1 | Scavenger assisted combinatorial process for preparing libaries of secondary amine compounds | ELI LILLY AND COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| EP-0816309-A1 | Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5250571-A | Administering to mammals | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | disclosed |
| CN-1054418-A | For with relate to (S)-go improvement of first fluoxetine | LILLY CO ELI (US) | 1991-09-11 | — | — | CN | disclosed |
| JP-H02193951-A | FLUOXETINE ANALOGUE | ELI LILLY & CO | 1990-07-31 | — | — | JP | disclosed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096019-A1 | Methods of using norfluoxetine | NGF, TPH2, ALOX5 | HRH1 521/4885RIPK1 4867/4885LMNA 3632/4885 |
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | HPD, HNMT, PNMT | HRH1 16/4885RIPK1 2233/4885LMNA 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.